Stella Sexton, a resident of Manheim Township in Lancaster County, is among the volunteers taking part in a clinical trial to test the safety, dosage, and immune response of Inovio’s COVID-19 vaccine, writes Jeff Hawkes for the Lancaster Online.

The Plymouth Meeting company is one of the very few that are already performing human testing of their potential vaccine.

For the mother of two, the decision to take part in the trials was not hard.

“Somebody has to do it,” she said.

Sexton joined more than 100 volunteers for the year-long Phase 1 clinical trial that was launched by Inovio after the company found that its vaccine produced antibodies in mice.

Before being inoculated, she was informed by Dr. Pablo Tebas, the trial’s principal investigator, that the vaccine was well tolerated by the first group of volunteers, but this did not mean they could rule out severe side effects.

Still, since she received the vaccine last week, the 41-year-old has not felt any side effects.

“It’s an uncertain future, but I feel like I’ve done my own small part to contribute data towards a possible vaccine,” said Sexton.

Read more about Inovio’s vaccine trials at the Lancaster Online by clicking here.

You Might Also Like

Bloomberg Businessweek: Plymouth Meeting’s Inovio’s COVID-19 Vaccine Among Most Promising

Plymouth Meeting’s Inovio Alleges Supplier Is Withholding Critical Information on COVID-19 Vaccine

Inovio’s Experimental COVID-19 Vaccine Given to Philadelphia Volunteers